Sectors

QURE
uniQure N.V.
48.68
2 x 34.63
2 x 53.50
bid
ask
-
0.04
0.08%
2 @ 04:56 PM
48.00 -0.68 (1.40%)
Ytd103.43%
1y198.10%
47.61
day range
48.86
8.73
52 week range
71.50
Open48.23Prev Close48.72Low47.61High48.86Mkt Cap3.38B
Vol1.64MAvg Vol1.87MEPS-4.06P/EN/AForward P/E-16.25
Beta0.94Short Ratio7.97Inst. Own97.63%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0950-d Avg44.53200-d Avg27.951yr Est69.84

QURE News

Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?
zacks.com
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?

uniQure (QURE) reported earnings 30 days ago. What's next for the stock?

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
seekingalpha.com
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds

9 Health Care Stocks Whale Activity In Today’s Session
benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
zacks.com
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130

benzinga.com
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75

Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the pr

benzinga.com
Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target

Wolfe Research analyst Rudy Li upgrades uniQure (NASDAQ:QURE) from Peer Perform to Outperform and

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More
247wallst.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise

benzinga.com
Barclays Maintains Overweight on uniQure, Lowers Price Target to $60

Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the pr

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
seekingalpha.com
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure Q2 Earnings Call Highlights
marketbeat.com
uniQure Q2 Earnings Call Highlights

uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential a

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
zacks.com
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate

benzinga.com
uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate

uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consen

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
globenewswire.com
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for

uniQure to Announce Second Quarter 2026 Financial Results
globenewswire.com
uniQure to Announce Second Quarter 2026 Financial Results

~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earn

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
zacks.com
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business

Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
zacks.com
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?

QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulat

QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
zacks.com
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway

QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and c

uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
zacks.com
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?

uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from

Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

benzinga.com
HC Wainwright & Co. Maintains Buy on uniQure, Raises Price Target to $80

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy an

What's Going On With Capricor Therapeutics Stock On Friday?
benzinga.com
What's Going On With Capricor Therapeutics Stock On Friday?

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
globenewswire.com
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

benzinga.com
Mizuho Maintains Outperform on uniQure, Raises Price Target to $68

Mizuho analyst Uy Ear maintains uniQure (NASDAQ:QURE) with a Outperform and raises the price targ

uniQure Announces Pricing of Upsized $225 Million Public Offering
globenewswire.com
uniQure Announces Pricing of Upsized $225 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday
benzinga.com
Backblaze, Infleqtion, Zeta Global And Other Big Stocks Moving Higher On Tuesday

Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal w

uniQure Announces $150 Million Proposed Public Offering
globenewswire.com
uniQure Announces $150 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
benzinga.com
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy

uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related se

QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
zacks.com
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy

uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reduc

Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
benzinga.com
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap

QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
zacks.com
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval

QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
globenewswire.com
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early b

uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy
benzinga.com
uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy

benzinga.com
Barclays Upgrades uniQure to Overweight, Raises Price Target to $65

Barclays analyst Eliana Merle upgrades uniQure (NASDAQ:QURE) from Equal-Weight to Overweight and

benzinga.com
Goldman Sachs Maintains Neutral on uniQure, Raises Price Target to $46

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and raises t

benzinga.com
Leerink Partners Maintains Outperform on uniQure, Raises Price Target to $70

Leerink Partners analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and ra

UniQure: AMT-130's FDA Path Reaffirms My Bull Case
seekingalpha.com
UniQure: AMT-130's FDA Path Reaffirms My Bull Case

QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-te

benzinga.com
RBC Capital Maintains Outperform on uniQure, Raises Price Target to $65

RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and raises the pr

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Crude Oil Edges Higher; US Retail Sales Top Estimates
benzinga.com
Crude Oil Edges Higher; US Retail Sales Top Estimates

U.S. stocks up, Dow Jones gains 0.39%. NASDAQ rose 0.09%, S&P 500 up 0.11%. Industrials shares j

FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
benzinga.com
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval

uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval f

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
uniQure To Submit BLA In Q3 2026 For AMT‑130 Huntington's Therapy After FDA Accepts 3‑Year Phase I/I

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Ap

7 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
7 Health Care Stocks With Whale Alerts In Today's Session

benzinga.com
Watching uniQure; Shares See A Spike In Volume, Endpoints News Reports "Acting FDA Commissioner Pled

https://endpoints.news/acting-fda-commissioner-pledges-to-prevent-political-interference-in-rare-dis

Replimune, Dell Technologies, NetApp And Other Big Stocks Moving Higher on Friday
benzinga.com
Replimune, Dell Technologies, NetApp And Other Big Stocks Moving Higher on Friday

US stocks up, Dow Jones up 171 pts. Replimune Group rises after FDA agreement. Other big gainers inc

10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session

benzinga.com
'Makary's Time Atop FDA Over, Diamantas Named Acting Commissioner' - Politico

https://subscriber.politicopro.com/article/2026/05/makarys-time-atop-fda-over-tktk-named-acting-comm

benzinga.com
'Trump Approves Plan To Fire FDA Commissioner Marty Makary, Sources Say' - CBS

https://www.cbsnews.com/news/trump-approves-plan-to-fire-fda-commissioner-marty-makary/?intcid=CNM-0